Miraculins Inc. and Cachet Sign LOI for China Rights to Diabetes Test

Published: Oct 16, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 15, 2013 -- Miraculins, a Canadian maker of non-invasive diagnostic tests, has signed a Letter of Intent to sell China rights for a diabetes test to Cachet Pharma, a China drug distributor. Miraculins acquired rights to the SCOUT DS® technology less than two months ago. SCOUT is a non-invasive test that measures changes in a person’s skin to indicate prediabetes and diabetes type 2. More details....

Stock Symbols: (TSX-V: MOM) (SHE: 002462)

Help employers find you! Check out all the jobs and post your resume.

Back to news